Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Novartis
Sponsor:
Information provided by (Responsible Party):
Novartis
ClinicalTrials.gov Identifier:
NCT01448057
First received: October 5, 2011
Last updated: April 2, 2014
Last verified: April 2014

October 5, 2011
April 2, 2014
July 2013
July 2014   (final data collection date for primary outcome measure)
Physician Global evaluation of effectiveness on Nasal Symptoms [ Time Frame: up to 3 days ] [ Designated as safety issue: No ]
The Physician will measure the reduction of Nasal Symptoms (Nasal Congestion, Sneezing, and Rhinorrhea) on day 2
Sum of subject self-assessments of intensity of individual nasal symptoms using 100 mm VAS [ Time Frame: up to 3 days ] [ Designated as safety issue: No ]
Subject will assess nasal symptoms using a 100 mm visual analog scale.
Complete list of historical versions of study NCT01448057 on ClinicalTrials.gov Archive Site
Sum of subject self assessment using a 100 mm Visual Analog Scale [ Time Frame: up to 3 days ] [ Designated as safety issue: No ]
Subject will assess Nasal Symptoms using a 100 mm Visual Analog Scale
Subject self-assessments using 100-mm VAS 2 hours after the 4th dose. [ Time Frame: up to 3 days ] [ Designated as safety issue: No ]
Subject to assess nasal symptoms using a 100 mm visual analog scale 2 hours after the 4th dose.
Not Provided
Not Provided
 
Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu
A Prospective, Randomized, Investigator-Blind Study to Compare Three Days of Treatment With Paracetamol (500 mg) / Dimethindene Maleate (1 mg) / Phenylephrine Hydrochloride (10 mg) Tablets Versus Paracetamol 500 mg Alone in the Treatment of Nasal Congestion and Other Symptoms Due to Cold and Flu

The study is a clinical evaluation of an over the counter (OTC) combination product containing paracetamol (500 mg), dimethindene maleate (1 mg), phenylephrine hydrochloride (10 mg) compared to paracetamol (500 mg) alone in the treatment of nasal congestion, rhinorrhea, sneezing and other symptoms due to upper respiratory tract infection (URTI).

Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
  • Upper Respiratory Tract Infection
  • Nasal Congestion
  • Rhinorrhea
  • Sneezing
  • Drug: Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
    Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
  • Drug: Paracetamol (500 mg) tablets
    Paracetamol (500 mg) tablets
  • Experimental: Arm A
    Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
    Intervention: Drug: Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
  • Active Comparator: Arm B
    Paracetamol (500 mg) tablets
    Intervention: Drug: Paracetamol (500 mg) tablets
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
244
July 2014
July 2014   (final data collection date for primary outcome measure)
  • Inclusion criteria:

    • acute URTI, diagnosed by a health care professional at the study site, with the following symptoms having started within 72 hours before the screening/baseline Visit: nasal congestion, sneezing, and rhinorrhea.

  • Exclusion criteria:

    • Use of other investigational drugs within 30 days or 10 half-lives before enrollment, whichever is longer.
    • History of or known hypersensitivity to any of the study drugs, excipients or to drugs of similar chemical classes.

Other protocol-defined inclusion/exclusion criteria may apply

Both
18 Years to 65 Years
No
Contact: Eric Guenin 9735037169 eric.guenin@novartis.com
Brazil
 
NCT01448057
381-A-301
No
Novartis
Novartis
Not Provided
Not Provided
Novartis
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP